Durata Therapeutics to Present Six Dalbavancin Posters at the 24th Annual ECCMID Meeting

Durata Therapeutics, Inc. Logo

CHICAGO, May 2, 2014 (GLOBE NEWSWIRE) -- Durata Therapeutics, Inc. (Nasdaq:DRTX) today announced that data from two clinical trials of the company's lead product candidate, dalbavancin, will be presented in six posters at the 24th Annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), which takes place in Barcelona, Spain from May 10-13, 2014.

The following posters will be presented:

May 10-13, 2014

Title: Treatment of acute bacterial skin and skin structure infection (ABSSSI) with dalbavancin in an outpatient setting

Authors: M. Dunne, S. Puttagunta, M. Wilcox, H. Boucher, G.Talbot

Poster #: eP408

Title: Dalbavancin for the treatment of complicated skin and soft tissue infections in patients with and without diabetes mellitus in the DISCOVER studies

Authors: M. Dunne, S. Puttagunta

Poster #: eP409

Saturday, May 10, 2014

Title: Are Staphylococcus aureus PVL toxin-positive isolates causing acute bacterial skin and skin structure infections (ABSSSI) associated with more severe presentation or worse outcome

Authors: S. Puttagunta, H. Boucher, M. Wilcox, G.Talbot, M. Dunne

Poster #: P0193

Tuesday, May 13, 2014

Title: Geographic differences in the presentation and outcomes of acute bacterial skin and skin structure infections (ABSSSI) in the DISCOVER program

Authors: S. Puttagunta, G.Talbot, M. Wilcox, H. Boucher, M. Dunne

Poster #: P1818

Title: Clinical presentation and outcomes by subtype of infection in patients with acute bacterial skin and skin structure infections (ABSSSI) in the DISCOVER program

Authors: Authors: S. Puttagunta, G.Talbot, M. Wilcox, H. Boucher, M. Dunne

Poster #: P1819

Title: Clinical presentation of acute bacterial skin and skin structure infections (ABSSSI) by baseline pathogen in the DISCOVER program

Authors: Authors: S. Puttagunta, G.Talbot, M. Wilcox, H. Boucher, M. Dunne

Poster #: P1820

Copies of these posters will be available on Durata's website following the ECCMID meeting: www.duratatx.com.

About Dalbavancin

Dalbavancin is an intravenous antibiotic product candidate under investigation for once-weekly dosing, which we believe may facilitate the treatment of patients with ABSSSI in both the in-patient and out-patient settings, potentially reducing the length of a patient's hospital stay or avoiding hospital admission altogether, with an impact on the overall cost of care for these patients.

About Durata Therapeutics, Inc.

Durata Therapeutics is a pharmaceutical company focused on the development and commercialization of new therapeutics for patients with infectious diseases and acute illnesses. Durata has completed two global Phase 3 clinical trials with its lead product candidate, Dalvance, under investigation for the treatment of patients with acute bacterial skin and skin structure infections caused by susceptible Gram-positive bacteria. For more information about the company, visit www.duratatx.com.

Forward-looking Statements

Statements contained in this press release contain forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this press release, including statements regarding our strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management, are forward-looking statements. The words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.

CONTACT: Investor Relations and Public Affairs Contact Allison Wey Durata Therapeutics Vice President, Investor Relations and Public Affairs (312) 219-7017 awey@duratatx.com Media Relations Contact Geoff Curtis DJE Science (312) 233-1253 geoff.curtis@djescience.com

Source:Durata Therapeutics, Inc.